TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01867606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serum-derived bovine immunoglobulin protein isolate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03588065

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: FMS
Description: The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICS
Description: The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONFERENCE
Description: The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
Study: NCT03256344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Virally based anti-cancer immunotherapy given by direct injection into tumors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Virally based anti-cancer immunotherapy given by direct injection into tumors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A monoclonal antibody given by intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A monoclonal antibody given by intravenous injection.
Study: NCT01120275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03699735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bolero B90-SP
Description: Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bolero B90-SP
Description: Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bolero B90-SP
Description: Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
Study: NCT03585361

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health centers provide PPFP counseling and services
Description: Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health centers provide PPFP counseling and services
Description: Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
Study: NCT01043926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
Study: NCT03802916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone DR tablets 1000 mg (Low dosage)
Description: Deferiprone DR tablets 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone DR tablets 1000 mg (High dosage)
Description: Deferiprone DR tablets 1000 mg
Study: NCT03064009

Intervention type: OTHER
Intervention: Infection
Description: This is an observational trial
Study: NCT03947463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS block
Description: After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
Study: NCT00757016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution
Study: NCT02494492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravitreous administration of regulator T-cells
Description: The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
Study: NCT04433195

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test
Description: Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xpert MTB/RIF test
Description: Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
Study: NCT01955551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory Guidance on Child Development
Description: In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
Study: NCT03906071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
Study: NCT01043926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
Study: NCT03585361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEWs provide PPFP counseling and services
Description: HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteers (Development Army) promote PPFP
Description: HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health centers conduct data reviews
Description: Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health centers conduct data reviews
Description: Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEWs and volunteers track PPFP
Description: HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
Study: NCT02634216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capros
Description: 250 mg BID
Study: NCT00956449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: 1 dose of Influenza Vaccine Surface Antigen, Inactivated
Study: NCT01706445

Intervention type: OTHER
Group type: OTHER
Intervention: Other
Description: inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
Study: NCT00430625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPRIV ®,
Description: Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
Study: NCT02646670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: - In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: - In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
Study: NCT02646670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab and Aflibercept
Description: - The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept and ranibizumab
Description: - In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Study: NCT00562250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, once daily, single dose
Study: NCT03170102

Intervention type: OTHER
Group type: OTHER
Intervention: Building capacity through education
Description: Participants engaged in 2 webinars and 3 online discussions following reading selected material.
Study: NCT02538237

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2% mouthwash
Study: NCT04022031

Intervention type: DRUG
Intervention: Chinese patent medicine
Description: Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
Study: NCT00562250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablets, Oral, 4 mg, once daily, single dose
Study: NCT02626208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nestorone®/Estradiol Contraceptive Vaginal Ring
Description: Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nestorone®/Estradiol Contraceptive Vaginal Ring
Description: Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
Study: NCT00562250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin + Glimepiride
Description: Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
Study: NCT01617434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Study: NCT02144350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Hyperbaric Air
Description: Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
Study: NCT03967925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Sub-cutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV infusion 1g x 2
Study: NCT03010670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Study: NCT01348282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
Study: NCT01752842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for fenofibrate
Study: NCT03900559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines
Description: NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines
Description: NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes.
Study: NCT01053546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study: NCT01937130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01135953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
Study: NCT03010670

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Study: NCT01074372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 4 cohorts (dose 1, 2, 3, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 4 cohorts (dose 1, 2, 3, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 4 cohorts (dose 1, 2, 3, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 4 cohorts (dose 1, 2, 3, 4)
Study: NCT01135953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct Stimulation (tDCS) and D-cycloserine
Description: Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session.
Study: NCT01074372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 cohorts (dose 1, 2, 3, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 cohorts (dose 1, 2, 3, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 cohorts (dose 1, 2, 3, 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 cohorts (dose 1, 2, 3, 4)
Study: NCT04693117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.